Navigating the world of cell and gene therapy development and commercialisation

By Annabel Kartal-Allen | Published: 27-Sep-2024
Cell & Gene Therapy

Manufacturing Chemist’s Annabel Kartal-Allen (AKA) spoke to Adam Goldstein (AG), Senior Director of R&D Collaborations at Thermo Fisher Scientific, about the current trends in CGT manufacturing and how to optimise and commercialise the process

You need to be a subscriber to read this article.
Click here to find out more.

Initially discussing the latest trends in the biopharma industry, Adam notes that process analytical technology (PAT) has seen significant evolution in recent years and become an important component in terms of accelerating development timelines. PAT solutions enable the simple scaling of manufacturing processes to facilitate the production of biologics and cell and gene therapies (CGTs).

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Thermo Fisher Scientific
See more

You may also like

Manufacturing

Thermo Fisher Scientific enhances biologics manufacturing sustainability with biobased solutions

Read more
The single use, plant-based film for bioprocessing containers can reduce the carbon footprint of biologics manufacturing by eliminating the need for plastic resin

Trending Articles

  1. Clean Cells acquires cytogenic testing specialist, Karyologic The strategic acquisition will expand Clean Cells' US footprint, while allowing the company to offer karyotyping services to its North American clients
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Three areas of genomic medicine benefiting from the sequencing tech revolution One of the great challenges of modern medicine, despite significant advances in many therapeutic areas, is that some diseases remain stubbornly difficult to treat. Neil Ward, Vice President, EMEA, at PacBio, investigates
  3. Opening new doors to precision medicine with single-stranded DNA (ssDNA): part II In the second part of this article, the benefits of ssDNA in terms of efficient cellular uptake and stability, the application of self-folding nanocarriers for gene delivery and mechanisms of action are discussed, along with a forward-thinking review of future perspectives and challenges
  4. Opening new doors to precision medicine with single-stranded DNA (ssDNA): part I In this two-part article, the science behind ssDNA manufacturing is explored, along with the innovations that are enhancing the therapeutic benefits of ssDNA-derived constructs. A comparative analysis of traditional double-stranded DNA (dsDNA) and other nucleic acid-based methods is also included
  5. AskBio's Parkinson's gene therapy, AB-1005, receives FDA RMAT designation The Bayer subsidiary is currently recruiting for the Phase II REGENERATE-PD trial, which will assess AB-1005's potential in slowing Parkinson's disease progression and improving motor outcomes

Upcoming event

Making Pharmaceuticals

29-30 April 2025 | Conference | Coventry, UK See all

You may also like

Manufacturing

Thermo Fisher Scientific enhances biologics manufacturing sustainability with biobased solutions

The single use, plant-based film for bioprocessing containers can reduce the carbon footprint of biologics manufacturing by eliminating the need for plastic resin
Manufacturing

Multiply Labs and Thermo Fisher Scientific expand partnership to automate cell expansion and separation

Automating GMP-ready instruments using robotic technology helps reduce costs and accelerates timelines
Finance

Funding for commercialisation of Rexgenero cell therapy

TrakCel, a specialist software developer for cell and gene therapy supply chain tracking and orchestration, announced the consortium comprising itself, the Cell and Gene Therapy (CGT) Catapult, Rexgenero and Fisher Bioservices (part of Thermo Fisher Scientific) has secured funding of £1.4 million from Innovate UK
Research & Development

New pluripotent stem cell media eliminates need for daily feeding

Allows two full-day breaks without changes to set up or protocol
Manufacturing

Accellta grants feeder-free stem cell culture medium rights to Thermo Fisher

Stem cell company grants worldwide non-exclusive rights to Thermo Fisher to manufacture and distribute its proprietary cell culture medium and ancillary products and methods
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Bringing CAR-T therapy within reach: how decentralised manufacturing will improve patient access

By offering a lifeline to patients with otherwise untreatable conditions, CAR-T cell therapy has transformed cancer treatment. Yet, despite the breakthrough potential of these patient-specific therapies, access remains severely limited
You need to be a subscriber to read this article.
Click here to find out more.
Cell & Gene Therapy

Three areas of genomic medicine benefiting from the sequencing tech revolution

One of the great challenges of modern medicine, despite significant advances in many therapeutic areas, is that some diseases remain stubbornly difficult to treat. Neil Ward, Vice President, EMEA, at PacBio, investigates
Subscribe now